UPDATE: Oppenheimer Downgrades Body Central to Perform on on Lower Q4 Guidance
Oppenheimer downgraded Body Central Corp. (NASDAQ: BODY) from Outperform to Perform.
Oppenheimer noted, "This morning, ahead of its participation at the ICR XChange Conference this Wednesday, January 16th, at 9:25 AM, BODY lowered 4Q EPS guidance to $0.10 (from $0.19-$0.22) and vs. Opco/consensus estimates of $0.28/$0.23. December proved to be especially challenging at the expense of margins and the turnaround is now taking longer to gain traction than initially expected. While we have confidence in the LT fundamentals and initiatives in place to support growth, we are stepping to the sidelines until we gain further visibility. Downgrading to Perform from Outperform and rescinding our price target."
Body Central closed at $9.71 on Monday.
Latest Ratings for BODY
|Oct 2013||Piper Jaffray||Maintains||Neutral|
|Sep 2013||Dougherty & Company||Downgrades||Buy||Neutral|
|Jul 2013||SunTrust Robinson Humphrey||Initiates Coverage on||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.